Oppenheimer analyst Colin Rusch downgrades Tesla (NASDAQ:TSLA) from Outperform to Perform.
Selecta Biosciences Narrows R&D Focus On Gout Candidate
Selecta Biosciences Inc (NASDAQ: SELB) provided an update on its ongoing strategic initiative to maximize stockholder value related to its economic interests in SEL-212, which is being developed for the treatment of chronic refractory gout, which Selecta